---
document_datetime: 2023-09-21 18:19:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/adrovance-epar-procedural-steps-taken-authorisation_en.pdf
document_name: adrovance-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3840955
conversion_datetime: 2025-12-20 02:27:46.986964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd. submitted on 28 June 2006 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for ADROVANCE, through the centralised procedure.

The  legal  basis  for  this  application  refers  to  Article  10c  of  Directive  2001/83/EC,  as  amended  relating to informed consent from the marketing authorisation holder, Merck Sharp &amp; Dohme Ltd., for the authorised medicinal product FOSAVANCE (EU/1/05/310/001-005).

## Licensing status:

The  initial  product,  FOSAVANCE,  has  been  given  a  Community  Marketing  Authorisation  on 24 August 2005.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Ian Hudson

Co-Rapporteur:

Josef Suko

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 28 June 2006.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  18 September  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 22 September 2006.
- The procedure started on 21 July 2006.
- The Rapporteur circulated an updated Assessment Report to all CHMP members on 13 October 2006.
- The applicant provided on 17 October 2006 a letter of undertaking of the follow-up measures to be fulfilled post-authorisation.
- During  the  meeting  on  16-18  October  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to ADROVANCE on 18 October 2006.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 4 January 2007.